Eli Lilly partner urges investors to look beyond biotech turmoil
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
Pharmaceutical
Articles
Trump says new proposal will slash some U.S. drug prices
President Donald Trump said he was “taking aim at the global freeloading that forces American consumers to subsidize lower prices in foreign countries through higher prices in our country.”
Trump focusing on drug prices, high among voters’ concerns
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
Opioid alternative from Lilly, Pfizer shows promise in study
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
U.S. wants drug prices in TV ads: ‘Patients deserve to know’
The drug industry's main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they'll start doing that next spring.
Deal with national pharmacy spurs tech company’s growth
An Indianapolis-based company has signed a deal with national mail-order pharmacy GoGoMeds that officials project will help double its local workforce—to about 250—within five years.
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Opioid epidemic showing signs of turning corner, state drug czar says
Visits to emergency rooms in Indiana for drug overdoses are falling, and doctors are writing fewer prescriptions for opioid painkillers, Jim McClelland said Friday.
Migraine drug from Eli Lilly approved by FDA
Eli Lilly and Co. received clearance Thursday from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
Competitor beats Lilly to market with migraine drug approval
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
Hc1.com dives deeper into opioid data, precision care
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
Indiana experiences record year for drug overdose deaths
Overdose deaths in Indiana rose 18 percent last year compared with 2016 and 37 percent over 2015. A vast majority of the overdoses were caused by opioids.
Health care exchange-traded fund hits record as pharma soars
A boom in major U.S. pharmaceutical stocks is creating a swarm of activity around an exchange-traded fund tracking major drugmakers like Eli Lilly and Co.
China cuts red tape, increases potential for breakthrough medicines
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
New Lilly R&D chief planning blitz of drug launches
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
Trial of potential Alzheimer’s treatment shows rare positive results
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
Lilly unveils new $75M research building in Indianapolis
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
Another experimental Alzheimer’s drug fails as Eli Lilly, Astra halt tests
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
In setback for Lilly, FDA limits dosage, slaps warning on new arthritis drug
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
Gene therapies that could transform diseases get easier FDA path
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.